GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep

Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex

Laurus Labs acquires 87.59% stake in Laurus Bio Private

Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders

DxVx plans to make a license-in agreement of OVM-200

Final stage in licensing OVM-200 from Oxford Vacmedix in the UK

Merck to acquire Caraway Therapeutics

Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases

Fosun Pharma USA and Treehill Partners to invest in biopharma space

The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market

Evive Biotech and Acrotech Biopharma receive FDA approval of Ryzneuta

Azelis inks distribution agreement with Beneo in India and Bangladesh

Azelis will be the exclusive distributor for inulin, oligofructose, scFOS, texturized wheat proteins, faba beans, Beta-glucans, meatless solution

LTTS, NVIDIA to unveil Gen AI and software defined architecture for medical devices

This innovative solution comes as an answer to the industry-wide challenges of availability, cost, and dependencies linked to custom and proprietary hardware components

AstraZeneca launches health-tech business ‘Evinova’

Evinova will operate as a separate health-tech business within AstraZeneca

Oceanic-AF study stopped early due to lack of efficacy

OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program